

Special Issue

Clinical Challenges and Advances in Dry Eye Disease and Meibomian Gland Dysfunction

Message from the Guest Editors

This Special Issue aims to explore recent breakthroughs in the understanding, diagnosis, and treatment of OSD. It will feature original research and reviews on innovative diagnostic tools such as tear biomarkers, advanced imaging techniques, and artificial intelligence in OSD assessment. Moreover, the issue will highlight novel therapeutic strategies, including biologics, regenerative medicine approaches, and next-generation lubricants. A strong emphasis will be placed on integrating these advancements into patient-centered care, addressing real-world challenges such as accessibility, adherence, and personalized treatment regimens. Contributions will also examine the psychosocial impact of OSD, providing a holistic perspective on managing this multifaceted condition. By bridging clinical research and practical application, this Special Issue aims to enhance the understanding of OSD and promote strategies that improve patient outcomes and quality of care.

Guest Editors

Dr. Salvatore Troisi

Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Scuola Medica Salernitana-U.O.C. di Oftalmologia, 84131 Salerno, SA, Italy

Dr. Livio Vitiello

Eye Unit, "Luigi Curto" Hospital, Azienda Sanitaria Locale Salerno, 84035 Polla, SA, Italy

Deadline for manuscript submissions

closed (31 December 2025)



Journal of Clinical & Translational Ophthalmology

an Open Access Journal
by MDPI



mdpi.com/si/231543

*Journal of Clinical &
Translational Ophthalmology*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcto@mdpi.com

[mdpi.com/journal/
jcto](https://mdpi.com/journal/jcto)





Journal of Clinical & Translational Ophthalmology

an Open Access Journal
by MDPI



mdpi.com/journal/

[jcto](https://mdpi.com/journal/jcto)



About the Journal

Message from the Editor-in-Chief

The primary objective of the *Journal of Clinical & Translational Ophthalmology (JCTO)* (ISSN 2813-1053) is to establish a forum that allows the basic science researcher to gain insight into current clinically relevant questions, while simultaneously providing clinicians with a better understanding of the underlying pathophysiology of the clinical presentations that they experience on a first-hand basis.

We look forward to publishing highinterest, peer-reviewed manuscripts covering a wide range of ophthalmic conditions, including original research papers, review articles, short communications, case studies, and commentaries. It is the intention of the Journal to encourage a robust response from the readership as it relates to these contemporary topics in order to provide a more dynamic experience that will undoubtedly contribute to the translational mission of the Journal.

Editor-in-Chief

Prof. Dr. Jack V. Greiner

1. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
2. Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA
3. Department of Surgery, University of New England College of Osteopathic Medicine, Biddeford, ME, USA
4. Clinical Eye Research of Boston, 5 Whittier Place, Suite 102, Boston, MA 02114, USA
5. Boston Ocular Surface Center, 955 Main Street, Suite 307, Winchester, MA 01890, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 42.8 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.